Overview

Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

200 women with PPH will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) and group 2 will receive oxytocin 10 IU (Syntocinon®, Novartis, Switzerland). The investigators will not include a control group for ethical reasons.

Phase:

Phase 3

Details

Lead Sponsor:

Cairo University

Treatments:

Ergonovine
Lactitol
Oxytocin